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The aim of this study was to evaluate the impact of abdominal compression (AC) on outcome in patients
treated with stereotactic body radiotherapy (SBRT) for primary lung cancer. We retrospectively reviewed data
for 47 patients with histologically proven non-small cell lung cancer and lung tumour motion ≥8 mm treated
with SBRT. Setup error was corrected based on bony structure. The differences in overall survival (OS), local
control (LC) and disease-free survival (DFS) were evaluated to compare patients treated with AC (n = 22) and
without AC (n = 25). The median follow-up was 42.6 months (range, 1.4–94.6 months). The differences in the
3-year OS, LC and DFS rate between the two groups were not statistically significant (P = 0.909, 0.209 and
0.639, respectively). However, the largest difference was observed in the LC rate, which was 82.5% (95% CI,
54.9–94.0%) for patients treated without AC and 65.4% (95% CI, 40.2–82.0%) for those treated with AC.
After stratifying the patients into prognostic groups based on sex and T-stage, the LC difference increased in
the group with an unfavourable prognosis. The present study suggests that AC might be associated with a
worse LC rate after SBRT using a bony-structure-based set-up.
Keywords: abdominal compression; clinical outcome; stereotactic body radiation therapy; non-small cell lung
cancer
INTRODUCTION
Stereotactic body radiotherapy (SBRT), a rapidly evolving
technique, has proven to be an efficient and effective alterna-
tive to surgery to treat early-stage lung cancer. Indeed, com-
pared with conventional radiotherapy, the high conformality
and precise radiation delivery in SBRT facilitates safer deliv-
ery of an ablative dose to the tumour while minimizing the
dose to the surrounding normal tissues, therefore achieving
better local control (LC) rates (similar to those obtained with
surgery) [1, 2]. Imaging and respiratory motion management,
especially for a moving target such as a lung tumour, play a
crucial role in achieving this high conformality.
Abdominal compression (AC) is a widely used respiratory
motion management technique in patients treated with SBRT
for lung cancer; its efficiency at reducing the amplitude of
respiratory-induced tumour motion has been reported in
many studies [3, 4]. However, some disadvantages have been
reported related to the use of AC [4–6]. According to
Bissonnette et al., AC can cause increased variation in
tumour motion [6]. In a larger series of patients with a larger
degree of tumour motion than the Bissonnette study, we
reported larger interfractional variations in tumour motion
amplitude in the group of patients treated with AC [5].
Heinzerling et al. reported difficulty in reproducing the com-
pression effects of AC over the course of an SBRT treatment
because of changes in the patient’s anatomy, girth, and re-
spiratory patterns during the treatment period [4]. These
changes may increase the probability of target underdosing
and overdosing of surrounding normal tissues. This is critic-
al, considering the high dose per fraction used in SBRT that
may affect the treatment outcome.
In this study, we retrospectively reviewed the data of
patients with histologically proven non-small cell lung
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cancer (NSCLC) who underwent SBRT with and without




With the approval of the Institutional Review Board of
Kyoto University Hospital, we reviewed the data of 98
patients with histologically proven NSCLC who had under-
gone SBRT in our institution between January 2004 and
March 2009. The eligibility criteria for SBRT treatment in
our institution have been described in previous reports [7].
Of the 98 patients, we retrospectively analysed 47 with
tumour motion ≥8 mm, who were potential candidates for
AC—see the treatment procedure section below. AC was
used in 25 (53.2%) of 47 patients. Of the remaining 22
patients, the reasons for avoiding AC were as follows: history
of abdominal surgery (n = 3), abdominal aortic aneurysm
(n = 2), unexpected increase in tumour motion (n = 3), in-
ability to significantly reduce the tumour motion amplitude
(n = 10), and discomfort (n = 1). In three patients, the oncolo-
gist judged the AC device unnecessary. We subsequently
divided the patients into two prognostic groups based on the
recursive partitioning analysis (RPA), as described by Matsuo
et al. [7]. RPA Class I with a favourable prognosis included
female or T1a tumour patients, and Class II included male
patients with T1b or T2a tumours. Patient characteristics are
summarised in Table 1.
Treatment protocol
Up until April 2008, all patients were positioned and immo-
bilised during simulation on a Stereotactic Body Frame
(Elekta, Stockholm, Sweden), and thereafter a BodyFix
vacuum cushion (Medical Intelligence, Schwabmunchen,
Germany) with both arms raised was used. They subsequent-
ly underwent fluoroscopic imaging under free breathing
using the Acuity Planning, Simulation, and Verification
System, version 8.1 (Varian Medical Systems, Palo Alto,
CA) to evaluate tumour motion. When the tumour motion
observed on X-ray fluoroscopy exceeded 8 mm in the longi-
tudinal direction, a pressure plate was used to attempt to
reduce the amplitude of motion, except in patients with ab-
dominal aneurysm or gallstones [3]. The pressure plate was
placed 3–4 cm below the costal margin of the ribs below the
xiphoid. The plate was connected by a graduated screw to a
bar that was firmly attached to the treatment couch
(BodyFix) or frame (Stereotactic Body Frame), the position
of which was reproduced at each treatment. The screw was
then tightened to compress the plate until the motion ampli-
tude was decreased sufficiently. The position of the screw
was recorded and reproduced during each treatment session
(Fig. 1) [5]. We ensured that the compression could be toler-
ated over the treatment course.
The internal target volume (ITV) was delineated according
to the image dataset obtained from a CT scan performed with
a slow scan technique and a gantry rotation time of 4 s, or
according to averaged intensity projection images derived
from a four-dimensional CT scan (4DCT), depending on
whether the treatment was planned before or after October
2006, respectively [8]. When the delineated ITV was found
to be insufficient to encompass the respiratory motion
observed on X-ray fluoroscopy, the ITVs were manually cor-
rected according to fluoroscopic tumour motion evaluation.
Planning target volumes (PTVs) were thereafter created by
adding 5-mm margins to the ITVs in all directions.
The treatment plans were made using Eclipse (Varian
Medical Systems) and calculated under heterogeneity cor-
rection using the Batho Power Law. They consisted of 5–8










Age (year) 77 (63–86) 77 (58–88) 0.563





Class I 14 13






Tumour diameter (mm) 21 (11–37) 25 (19–37) 0.049
Respiratory motion w/o
AC (mm)




AC = abdominal compression, RPA = recursive partitioning
analysis, Ad = adenocarcinoma, Sq = squamous cell carcinoma,
LC = large cell carcinoma, NOS = non-small cell lung cancer,
not otherwise specified. Values are shown in number or median
(range).
*P-value between respiratory motion in patients treated without
AC and that with AC in those treated with AC.
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non-coplanar, static 6-MV photon beams from the Clinac
2300C/D (Varian Medical Systems) for patients treated
before April 2008, and the Novalis system (BrainLAB,
Feldkirchen, Germany) thereafter. The treatment beam was
collimated to the PTV with a 5-mm margin using a multileaf
collimator to ensure a peripheral dose of the PTV. Set-up
correction was based on bony alignment using linacgraphy
for the Clinac 2300C/D and the ExacTrac X-Ray system
for the Novalis system. A total dose of 48 Gy in four frac-
tions was prescribed to the isocentre in a 1-week treatment
schedule with a median overall treatment time of 5 d
(range, 4–10 d).
Evaluation
The follow-up procedure has been previously described in
detail [7]. The follow-up period was defined as the period
from the first day of SBRT to the last follow-up visit or date
of death. Local recurrence was judged according to either
histology or chest CT images showing enlargement of the
tumour for at least 6 months. 18F-Fluorodeoxyglucose pos-
ition emission tomography (FDG-PET) was recommended
when local recurrence was suspected, but was not mandatory.
The time of LC was defined as the duration from the begin-
ning of SBRT treatment to the date of local recurrence.
Statistical analyses
The chi square test and the Mann–Whitney U test were used
to assess the significance of differences between the group of
patients treated with and without AC.
Overall survival (OS), LC and disease-free survival (DFS)
were estimated by the Kaplan–Meier method, and the differ-
ences between patient groups treated with and without AC
were assessed by the log–rank test. An R version 2.13.2 with
RcmdrPlugin.EZR package [9] was used for statistical ana-
lysis. Statistical significance was defined as P < 0.05.
RESULTS
The median follow-up period was 42.6 months (range, 1.4–
94.6 months). The 3-year OS, LC and DFS rates for all 47
patients were 52.4% (95% confidence interval [CI], 29.7–
70.9%), 82.5% (95% CI, 54.9–94.0%) and 38.1% (95% CI,
18.3–57.8%), respectively, for patients treated without AC
and 54.4% (95% CI, 32.9–71.6%), 65.4% (95% CI, 40.2–
82.0%) and 34% (95% CI, 16.3–52.6%), respectively, for
patients treated with AC (Fig. 2). The differences between
the two groups were not statistically significant (P = 0.909,
0.209 and 0.639, respectively). However, the largest differ-
ence between the two groups was observed in the LC rate.
After stratification according to the RPA, 57.4% of patients
were RPA Class I, and 42.6% were RPA Class II. In RPA
Class I, the LC rate was 83.1% (95% CI, 47.2–95.5%) for
patients treated without AC, and 75.5% (95% CI, 41.6–91.4%)
for patients treated with AC (P = 0.527, Fig. 3a). In RPA Class
II, the LC rate was 80.0% (95% CI, 20.4–96.9%) for patients
treated without AC, and 50.5% (95% CI, 13.6–79.2%) for
patients treated with AC (P = 0.394, Fig. 3b). T-stage distribu-
tion (T1a/T1b/T2a) in patients who experienced local recur-
rence was 1/2/0 in the group without AC, and 2/1/4 in the AC
group, respectively.
DISCUSSION
Although AC efficiently reduced the overall amplitude of
tumour motion, the day-to-day reproducibility of its com-
pression remains questionable [4]. This may result in greater
interfraction variation in tumour motion and geometric miss
in the dose delivery [6]. Moreover, Bouilhol et al. reported
minor benefits or even unwanted effects, such as increased
tumour motion and ITV for tumours located far from the dia-
phragm [10]. Considering the above disadvantages, the
current study investigated the impact of the use of AC on
clinical outcome. Several retrospective and prospective
studies of the clinical outcomes of using SBRT to treat lung
cancer have been published [11–15]. However, the present
Fig. 1. Photograph of patients immobilised with Stereotactic
Body Frame (a) and BodyFix (b) with the abdomen compressed.
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study is, to our knowledge, the first to compare the clinical
outcome between patients treated with and without AC while
undergoing SBRT for lung cancer.
The 3-year OS rate reported in the literature ranges from
43–60% [11–15].Onimaru et al. [11], using 48 Gy in four frac-
tions over 1 week, reported an OS rate of 53%. The present
study, using the same dose fractionation schedule, demon-
strated 3-year OS rates of 52.4% and 54.4% for patients treated
without and with AC, respectively. The 3-year OS rate in
patients treated without and with AC was consistent with
recent reports; the use of AC did not affect the OS rate. We also
found no difference in the 3-year DFS between the two groups.
Fig. 3. Local control in patients treated with (w/AC) and without
abdominal compression (w/o AC) after stratification, according to
the recursive partitioning analysis (RPA); RPA Class I (a) and RPA
Class II (b).
Fig. 2. Overall survival (a), local control (b) and disease-free
survival (c) comparing those treated with (w/AC) with those
treated without abdominal compression (w/o AC) including all
47 patients.
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However, our main finding was the large difference in the
3-year LC rate between patients treated with and without AC.
The 3-year LC rate was 82.5% for patients treated without
compression for a median follow-up period of 42.6 months.
This is consistent with previous reports. However, the LC
rate was 65.4% in patients treated with AC, which was lower
than reported previously. To account for possible confound-
ing factors between the group treated with AC and the one
treated without, we stratified the patients according to prog-
nostic groups based on RPA, as described by Matsuo et al.
[7]. Patients in the RPAClass I group with a better prognosis
had better LC rates than those in RPA Class II, regardless
of the use of AC. In both RPA Class I and RPA Class II
groups, the LC rate was higher in patients treated without
than in those treated with AC, with a larger difference
between the two groups in the RPA Class II patients. This
suggests that RPA Class II patients may be more sensitive to
the negative effects of AC, although the difference between
the two groups was statistically insignificant.
We previously reported greater interfraction variation in
lung tumour position in patients treated with abdominal com-
pression in the absence of soft tissue target matching [5].
Ikushima et al. evaluated the changes in soft tissue tumour
position during hypofractionated, in-room, CT-guided SBRT
for lung cancer [16]. They reported a trend in ITV movement
in any direction of more than 5 mm away from the original
position from the first fraction to the last fraction in more
than 20% of the patients when soft-tissue-based alignment
was not used. In the present study, the treatment for all
patients was based on bony alignment. Therefore, the use of
AC in addition to the lack of daily soft tissue image guidance
may explain the worse LC rate observed in the group of
patients treated with AC. Our institution currently uses cone-
beam computed tomography for tumour-based setup.
The results of the present study should, however, be inter-
preted with caution because of the small sample size and
also due to subtle differences between the two groups, such
as a larger initial degree of tumour motion in patients treated
with AC. Although the motion was reduced after the use of
AC, we cannot confirm that the negative impacts of larger
degrees of motion were also prevented. Moreover, a greater
proportion of patients with T2a tumours in the group of
patients treated with AC may have possibly influenced the
outcomes in this particular group.
AC efficiently reduces tumour motion, and therefore
decreases the chance of toxicity. However, the effect of AC
on local control has not been investigated. Considering that
confounding factors could not be eliminated, the present
study suggests that AC potentially worsens local control.
Therefore we recommend recourse to an image-guided radio-
therapy technique allowing soft tissue target matching
during or immediately before treatment when AC is planned,
particularly for patients with an unfavourable prognosis.
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